Navigation Links
The flip side of AIDS cocktails – HAART regime damages live

HIV infected patients on highly active antiretroviral therapy (HAART regime) are forced to stop the treatment because of the toxic side effects of the treatment, which causes liver damage. According to a study led by Dr. Raymond T. Chung, who presented the findings at Digestive Disease Week in Atlanta last week, severe liver toxicity forced almost one in every four patients to stop the treatment.

Regimens that contained drugs called nonnucleoside reverse transcriptase inhibitors, especially nevirapine and efavirenz, were particularly hard on the liver, Chung and colleagues found. In more than 25% of the cases the HAART regime cost elevation of liver enzymes to more than five times the upper limit of normal resulting in severe liver toxicity.

The drug cocktails have however clearly improved the condition of the patient in terms of controlling the HIV disease but the side effects on liver forced many to stop treatment. Dr. Chung said the next step would be to see if there are factors that may help doctors predict which HIV infected patients are most at risk for severe liver toxicity with HAART. The idea would be to single out those patients who require close monitoring.


'"/>




Page: 1

Related medicine news :

1. Need for considering cardiovascular risks before giving HAART for HIV/aids patients
2. Combination regime may work against prostate cancer
3. Hormone regimen and how recently used may determine cancer risk
4. Cardiac events better treated with intense cholesterol-lowering regime
5. Simplest therapeutic regimen found less effective against HIV
6. Protective regimen for acute Graft-versus-host disease
7. Diet & Exercise regime Not Harmful For Overweight, Lactating Mothers Or their Infants
8. Food packaging with Bisphenol A damages the brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is ... KLS is a longtime supporter of the event. , "We are pleased that ... said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... community for those in the fight against cancer, has produced a seminal study ... HRA will release top-line findings in a webinar, Defining Compassionate Care Through ...
(Date:2/23/2017)... ... 2017 , ... Curemark, LLC announced today that the Blüm Study, a Phase ... 3-8 with Autism, is now enrolling at three new sites. These new sites are ... , “There are currently no approved drugs that address the core symptoms of ...
(Date:2/22/2017)... ... February 22, 2017 , ... Our high-octane society ... even the sharpest brain. , Power On, a mental performance enhancer from Modus ... the brain. Each capsule contains Cognizin® Citicoline, a branded form of the brain ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , February 23, 2017 The fast-growing ... the United States . According to the 2017 ... industry is expected to create 283,422 jobs by 2020, with ... over the next four years. The accelerating pace of cannabis ... growth of legal cannabis market, which will further create more ...
(Date:2/23/2017)... 2017 The top three players ... Healthcare, Koninklijke Philips N.V., and Schiller. Collectively, these companies ... market in 2015. Strong product portfolio and a monumental ... be aiding these players remain leaders in the fragmented ... in the global market are likely to focus on ...
(Date:2/23/2017)... Feb. 23, 2017   SeraCare Life Sciences ... in vitro diagnostics manufacturers and clinical laboratories, is ... Implementation of NGS-Based Tests" to be hosted by ... at 11am Eastern Standard Time (US). ... the need for improved performance and global standardization ...
Breaking Medicine Technology: